Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. 2010

V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza (MI), Italy. valentina.carozzi1@unimib.it

Cisplatin, paclitaxel and bortezomib belong to some of the most effective families of chemotherapy drugs for solid and haematological cancers. Epothilones represent a new family of very promising antitubulin agents. The clinical use of all these drugs is limited by their severe peripheral neurotoxicity. Several in vivo rat models have reproduced the characteristics of the peripheral neurotoxicity of these drugs. However, since only a very limited number of cancer types can be studied in immunocompetent rats, these animal models do not represent an effective way to evaluate, at the same time, the antineoplastic activity and the neurotoxic effects of the anticancer compounds. In this study, we characterized the neurophysiological impairment induced by chronic chemotherapy treatment in BALB/c mice, a strain suitable for assessing the activity of anticancer treatments. At the end of a 4-week period of treatment with cisplatin, paclitaxel, epothilone-B or bortezomib, sensory and sensory/motor nerve conduction velocities (NCV) were determined in the caudal and digital nerves and dorsal root ganglia (DRG) and sciatic nerves were collected for histopathological analysis. The electrophysiological studies revealed that all the compounds caused a statistically significant reduction in the caudal NCV, while impairment of the digital NCV was less severe. This functional damage was confirmed by the histopathological observations evidencing axonal degeneration in the sciatic nerve induced by all the drugs associated with pathological changes in DRG induced only by cisplatin and bortezomib. These results confirm the possibility to use our models to combine the study of the antineoplastic activity of anticancer drugs and of their toxic effects on the peripheral nervous system in the BALB/c mouse strain.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009413 Nerve Fibers, Myelinated A class of nerve fibers as defined by their structure, specifically the nerve sheath arrangement. The AXONS of the myelinated nerve fibers are completely encased in a MYELIN SHEATH. They are fibers of relatively large and varied diameters. Their NEURAL CONDUCTION rates are faster than those of the unmyelinated nerve fibers (NERVE FIBERS, UNMYELINATED). Myelinated nerve fibers are present in somatic and autonomic nerves. A Fibers,B Fibers,Fiber, Myelinated Nerve,Fibers, Myelinated Nerve,Myelinated Nerve Fiber,Myelinated Nerve Fibers,Nerve Fiber, Myelinated
D009431 Neural Conduction The propagation of the NERVE IMPULSE along the nerve away from the site of an excitation stimulus. Nerve Conduction,Conduction, Nerve,Conduction, Neural,Conductions, Nerve,Conductions, Neural,Nerve Conductions,Neural Conductions
D010523 Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves. Peripheral Nerve Diseases,Peripheral Neuropathies,PNS (Peripheral Nervous System) Diseases,PNS Diseases,Peripheral Nervous System Disease,Peripheral Nervous System Disorders,Nerve Disease, Peripheral,Nerve Diseases, Peripheral,Neuropathy, Peripheral,PNS Disease,Peripheral Nerve Disease,Peripheral Neuropathy
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D001897 Boronic Acids Inorganic or organic compounds that contain the basic structure RB(OH)2. Boronic Acid,Acid, Boronic,Acids, Boronic
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
January 1976, Proceedings of the Australian Association of Neurologists,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
October 2009, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
October 2019, Current opinion in neurology,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
January 2015, Journal of neuro-oncology,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
September 1996, Arquivos de neuro-psiquiatria,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
January 2001, Revista de neurologia,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
December 1999, Laboratory animal science,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
April 2012, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
April 2015, Revista da Escola de Enfermagem da U S P,
V A Carozzi, and A Canta, and N Oggioni, and B Sala, and A Chiorazzi, and C Meregalli, and M Bossi, and P Marmiroli, and G Cavaletti
May 2011, Expert opinion on drug safety,
Copied contents to your clipboard!